BioCryst Pharmaceuticals Inc (BCRX) stock
Close on Nov 13, 2026Market cap $1.94BP/E –Yield –
BioCryst Pharmaceuticals Inc grew revenue 60.3% to $961.51M over the twelve months to Sep 30, 2026. Operating income fell 480.3% to -$289.42M, moving the operating margin from 12.7% to -30.1%. Free cash flow was $365.85M, up 664.5% from a year earlier. At the latest close the market valued the company at $1.94B.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $1.94B
- P/E ratio
- –
- Price to sales
- 2.02
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- 18.81%
Fundamentals
- Revenue
- $961.51M
- Net income
- -$359.66M
- EPS, diluted
- -$1.42
- Free cash flow
- $365.85M
- Book value per share
- -$1.48
- Diluted shares
- 268M
Trading
- Next earnings
- Feb 25, 2027 (estimated, before the open)
- Previous close
- $7.68
- Open
- $7.67
- Day's range
- $7.49 – $7.75
- Volume
- 2,315,801
- Average volume (20 days)
- 5,772,460
- Index membership
- Russell 2000, Russell 3000
- Beta (5 years)
- 0.79
- 52-week range
- $6.23 – $11.22
- RSI (14 days)
- 40.7
- Volatility (1 year)
- 48.1%
- Relative volume
- 0.51×
- WACC
- 9.5%
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2011, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | BCRX | S&P 500 | Difference | BCRX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -5.7% | -3.0% | −2.7 pts | ||
| 3 months | -22.4% | -2.8% | −19.6 pts | ||
| Year to date | -2.4% | +11.5% | −13.9 pts | ||
| 1 year | +10.3% | +13.5% | −3.2 pts | ||
| 3 years | +47.8% | +77.7% | −29.9 pts | +13.9% | +21.1% |
| 5 years | -37.9% | +72.6% | −110.5 pts | -9.1% | +11.5% |
| 10 years | +42.5% | +308.2% | −265.7 pts | +3.6% | +15.1% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases BioCryst Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Update
- Results
- Update
- Results
About BioCryst Pharmaceuticals
Biological Products, (No Diagnostic Substances)
BioCryst Pharmaceuticals discovers, develops, and commercializes therapies targeting rare diseases and acute medical conditions. The company's lead commercial product, ORLADEYO, is an oral, once-daily therapy approved for the prevention of hereditary angioedema attacks in adult and pediatric patients. Its commercial portfolio also includes RAPIVAB, an intravenous neuraminidase inhibitor approved for the treatment of acute uncomplicated influenza. Additionally, the company advances a clinical pipeline of small-molecule and protein drug candidates for indications such as Netherton syndrome, diabetic macular edema, and atopic dermatitis. BioCryst distributes its therapies to patients through specialty pharmacy providers and collaborates with government bodies, commercial licensees, and healthcare distributors to supply medicines to global healthcare systems.
Company profile, executives and historyBioCryst Pharmaceuticals stock: common questions
What is BioCryst Pharmaceuticals's stock price?
BCRX closed at $7.61 on Nov 13, 2026, down 0.91% on the day. Over the past 52 weeks it traded between $6.23 and $11.22.
What is BioCryst Pharmaceuticals's market cap?
BioCryst Pharmaceuticals was worth $1.94B at the close on Nov 13, 2026: the share price times the diluted shares outstanding.
What is BCRX's P/E ratio?
BioCryst Pharmaceuticals lost money over the twelve months to Sep 30, 2026 (diluted EPS -$1.42), so it has no meaningful P/E ratio.
How much revenue does BioCryst Pharmaceuticals make?
BioCryst Pharmaceuticals reported revenue of $961.51M for the twelve months to Sep 30, 2026, up 60.3% from a year earlier.
Does BioCryst Pharmaceuticals pay a dividend?
No. BioCryst Pharmaceuticals has not paid a cash dividend over the last twelve months.
When does BioCryst Pharmaceuticals report earnings next?
BioCryst Pharmaceuticals is expected to report Q4 FY2026 results on Feb 25, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has BCRX stock performed over the past year?
Including dividends, BCRX returned +10.3% over the past year, against +13.5% for the S&P 500.
How many BCRX shares are sold short?
28M shares were sold short at the latest FINRA report, 11.03% of the float, or 5.1 days of average trading volume.
Who are BioCryst Pharmaceuticals's competitors?
Companies most similar to BioCryst Pharmaceuticals by business, industry and size include KRYS, INSM, KNSA, TVTX, BBIO.
See a number that looks wrong?